Mitochondrial Targeted Antioxidant Supplementation and Diastolic Function in Healthy Men and Women
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 31
- 试验地点
- 2
- 主要终点
- Changes in diastolic function
研究概览
简要总结
In this pilot study, the investigators will determine whether supplementation with a mitochondrial-targeted antioxidant (Mitoquinone (MitoQ)) improves mitochondrial function, left ventricular diastolic and vascular function.
详细描述
Heart failure affects over 5 million American adults and the risk of heart failure increases with age. Diastolic function typically declines with age. Targeting age-related causal factors leading to the decline in diastolic function in both women and men is a major public health initiative. In this pilot study, the investigators will determine whether supplementation with a mitochondrial-targeted antioxidant (Mitoquinone (MitoQ)) improves mitochondrial function, left ventricular diastolic and vascular function in older adults. As an exploratory aim, the investigators will determine whether there are differences between men and women in response to this supplementation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 50 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •50 - 75 years of age
- •sedentary-to-recreationally active (<3 days of vigorous exercise);
- •nonsmokers;
- •healthy, as determined by medical history, physical examination, standard blood chemistries.
排除标准
- •history of cancer
- •history of cardiovascular disease
- •unwilling or unable to take MitoQ supplement;
- •taking antioxidant vitamins, corticosteroids, or anti-inflammatory medications (e.g., aspirin);
- •taking sex hormone therapy
- •presence of menses within last 1 year;
- •taking any other medications (e.g., antihypertensives, lipid lowering medications) that would interact with MitoQ or impact CV function
结局指标
主要结局
Changes in diastolic function
时间窗: Baseline and 4 weeks
Echocardiographic measurements of LV function (and structure) will be assessed; primary outcomes include peak early (E) to late (A) mitral inflow velocity ratio and E to peak early (e') mitral annular velocity ratio.
次要结局
- Changes in endothelial function(Baseline and 4 weeks)
- Changes in arterial vascular coupling(Baseline and 4 weeks)
- Changes in brachial artery flow-mediated dilation(Baseline and 4 weeks)
- Changes in mitochondrial function(Baseline and 4 weeks)
- Changes in arterial stiffness(Baseline and 4 weeks)